ARIES - Ambrisentan in Patients With Moderate to Severe Pulmonary Arterial Hypertension (PAH)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT00091598 |
|
Recruitment Status :
Completed
First Posted : September 14, 2004
Last Update Posted : March 8, 2010
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Pulmonary Hypertension | Drug: Ambrisentan | Phase 3 |
Expanded Access : Gilead Sciences has indicated that access to an investigational treatment associated with this study is available outside the clinical trial.
ARIES-1 in North America and Australia
ARIES-2 in Western and Eastern Europe, South America and Israel
Subjects in these randomized studies will receive one of two doses of ambrisentan or placebo. Inclusion is not based on a specified WHO functional classification. Rather, subjects with WHO Class I-IV symptoms are eligible if their 6-minute walk distance is 150-450 meters and they meet the study-specified hemodynamic criteria. Subjects with anorexigen or HIV infection related PAH are eligible but subjects with congenital heart disease and pediatric subjects are excluded. The study requires a historical cardiac catheterization and other diagnostic procedures.
| Study Type : | Interventional (Clinical Trial) |
| Enrollment : | 372 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | Double |
| Primary Purpose: | Treatment |
| Official Title: | ARIES 1 and ARIES 2: Ambrisentan in PAH - A Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter, Efficacy Study of Ambrisentan in Subjects With Pulmonary Arterial Hypertension |
| Study Start Date : | January 2004 |
| Actual Primary Completion Date : | February 2006 |
| Actual Study Completion Date : | February 2006 |
- Change from baseline at Week 12 of six minute walk distance
- Change from baseline at Week 12 of:
- Borg Dsypnea Index
- WHO Functional Classification
- SF-36
- Time to Clinical Worsening
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Diagnosis of idiopathic PAH (formally known as PPH), or PAH associated with collagen vascular disease, anorexigen use, or HIV infection;
- Historical cardiac catheterization with the following hemodynamic criteria:
Mean pulmonary artery pressure greater than or equal to 25 mmHg; Pulmonary vascular resistance greater than 3 mmHg/L/min; Pulmonary capillary wedge pressure or left ventricular end diastolic pressure less than 15 mmHg;
- 6-minute walk distance of at least 150 meters, but no more than 450 meters;
- Total lung capacity greater than or equal to 70% and FEV1 greater than or equal to 65% of predicted normal;
Exclusion Criteria:
- Portopulmonary hypertension;
- Subjects with PAH due to or associated with coronary artery disease, left heart disease, interstitial lung disease, chronic obstructive pulmonary disease, veno-occlusive disease, chronic thromboembolic disease, or sleep apnea;
- Bosentan (Tracleer®), sildenafil (Viagra®), or chronic prostanoid therapy within 4 weeks of screening;
- Serum ALT or AST lab value that is greater than 1.5 times the upper limit of normal;
- Contraindication to treatment with an endothelin receptor antagonist;
- Subject with cardiovascular, hepatic, renal, hematologic, gastrointestinal, immunologic, endocrine, metabolic, or central nervous system disease that may adversely affect the safety of the subject;
- Participation in a clinical study involving another investigational drug within 4 weeks of screening.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00091598
Show 46 study locations
| Study Chair: | Lewis J. Rubin, MD | University of California San Diego, San Diego School of Medicine |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| ClinicalTrials.gov Identifier: | NCT00091598 |
| Other Study ID Numbers: |
ARIES |
| First Posted: | September 14, 2004 Key Record Dates |
| Last Update Posted: | March 8, 2010 |
| Last Verified: | March 2010 |
|
Pulmonary Arterial Hypertension |
|
Hypertension, Pulmonary Pulmonary Arterial Hypertension Hypertension Vascular Diseases Cardiovascular Diseases |
Lung Diseases Respiratory Tract Diseases Ambrisentan Antihypertensive Agents |